CCR2 and metabolic dysfunction-associated steatohepatitis: CCR2+ monocyte-derived macrophages are recruited to the liver (but also to the adipose tissue or atherosclerotic plaques) in metabolic disorders (29), making this pathway an attractive target for inflammatory therapies in NASH.